Grace Kagoro
ID: UNCST-2021-R013951
|
Improved mechanisms for climate change adaptation for sustainable food production
REFNo: NS705ES
Main Objective
1. To improve climate smart agriculture mechanisms and land management practices to cope with climatic variability.
Specific Objectives
1. To establish climatic related environmental hazards, risks & vulnerabilities in small holder farming of SW Uganda.
2. To determine climate smart agricultural practices for adoption to diversify and increase food production in climatic hazard-prone areas.
3. To optimize laboratory infrastructure for analytical capacities in soil, food profiling and plant micro-propagation at MUST.
4. To develop farmer-led crop production and climate monitoring systems for informed food production.
|
Uganda |
2024-06-05 17:47:58 |
2027-06-05 |
Natural Sciences |
Non-Clinical Trial |
Degree Award |
|
Linda Calabrese
ID:
|
Comparative analysis of FDI in Uganda
REFNo: SS1960ES
This research aims to understand whether investment from China is different from that from other countries in terms of its implications for host low- and middle-income countries (LMICs). I operationalise the research in the context of the spillovers generated by Chinese firms and foreign-non Chinese firms on domestic firms. I focus on spillovers because these are important channels of durable productivity transfers between foreign and domestic firms, but one that has mainly been investigated quantitatively and with little comparative analysis.
|
Italy |
2024-06-05 17:46:42 |
2027-06-05 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
PAULA NJERU
ID:
|
Utility of An Epilepsy Self-Management And Resilience Technical (SMART) APP for Adolescents and Young Adults
REFNo: HS3799ES
To identify specific improvements for the APP that will make it more useful for AWE and young adults.,To understand aspects of the APP that AWE and young adults derive the greatest benefit from.,To understand the perspectives of adolescents and young adults with epilepsy about using the SMART APP. ,To characterize the experiences of adolescents and young adults with epilepsy while using the SMART APP, pinpoint the essential elements of the APP that adolescents and young adults with epilepsy find most advantageous, and propose specific enhancements to further improve the APP,
|
Kenya |
2024-06-05 17:45:41 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Richard Rwabuhinga
ID:
|
Influence of Competency and performance on Employability in Uganda; A case study of Mountains of the Moon and United Pentecostal Universities
REFNo: HS3058ES
4. The establish the impact of competencies on interpersonal skills of graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda,3. To find out the influence of competence on problem solving skills of education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,2. To establish the influence of competence on communication skills among education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,1. To establish the influence of competence on academic skills among education graduates from Mountains of the Moon and United Pentecostal Universities in Mid-western Uganda.,
|
Uganda |
2024-06-05 17:44:09 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Cissy Kityo
ID: UNCST-2021-R013663
|
A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB
REFNo: HS3834ES
1.2 Secondary Objectives 1.2.1 Phase 2a and 2b: To evaluate the proportion of participants with a quantifiable RS ratio after therapeutic vaccination with ID93 + GLA-SE compared to placebo. 1.2.2 Phase 2a: To evaluate the kinetics of cellular immunogenicity of ID93 + GLA-SE through 12 months post second dose of study product. 1.2.3 Phase 2a: To evaluate the kinetics of humoral immunogenicity of ID93 + GLA-SE through 12 months post second dose of study product. 1.2.4 Phase 2a: To evaluate innate immune changes in response to ID93 + GLA-SE through 2 weeks post second dose of study product. 1.2.5 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE, to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, in subgroups defined by: Hard-to-treat phenotype and not hard-to-treat phenotype, where hard-to-treat phenotype is defined as smear Grade ≥3 and cavitary disease on chest radiograph at TB diagnosis.1.3 Exploratory Objectives 1.3.1 Phase 2a: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to: • The safety and immunogenicity of ID93 + GLA-SE in participants living with and without HIV. • The quantitative RS ratio at time points relative to vaccination and TB treatment as indicated in the Schedule of Evaluations (SOE). • The magnitude and quality of immune responses with respect to the composition of the intestinal microbiota. 1.3.2 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, adjusted for • Pharmacokinetics (PK) assessments of first-line TB drugs (exposure) during TB treatment as per the SOE. • Levels of participant adherence to standard of care (SOC) TB treatment measured using self-reporting and urine acetyl-isoniazid (AcINH) from start to end of TB treatment. 1.3.3 Phase 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to the proportion of participants with TB-related unfavorable outcomes at 540 days after study entry, which is approximately 18 months after start of TB treatment, stratified by bacterial burden at start of TB treatment. 1.3.4 Phase 2a and 2b: To develop the composite predictive model of TB drug response by using measures of adherence, drug exposure (PK), immune response, gut microbiota, and participant phenotype. 1.3.5 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to proportion of participants with sputum culture conversion at baseline at time of randomization and at Step 2, Days 30, 120, and 150, which are approximately 2, 5, and 6 months after start of TB treatment. 1.3.6 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to cumulative relapse from end of TB treatment up to end of study follow-up, that is, Step 2, Days 420, 450, 480, and 510, for Groups 1, 2, 3 (&5), and 4 (&5), respectively. 1.3.7 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to lung function and health-related quality of life, as measured by spirometry and the St. George’s Respiratory Questionnaire. 1.3.8 Phase 2a and 2b: To compare the within-person change in lung function tests over time from the first dose of therapeutic vaccination with ID93 + GLA-SE to placebo. 1.3.9 Phase 2a and 2b: To compare therapeutic vaccination with ID93 + GLA-SE to placebo, with respect to resolution of transcriptomic biomarkers of TB disease. 1.3.10 Phase 2b: To identify correlates of protection for unfavorable TB outcomes. 1.3.11 Phase 2b: To estimate the effect of the vaccine on the proportion of participants with TB-related unfavorable outcomes among participants living with and without HIV. 1.3.12 Phase 2a and 2b: To conduct analyses related to furthering the understanding of TB, HIV, immunology, vaccines, and clinical trial conduct.,1.1 Primary Objectives 1.1.1 Phase 2a and 2b: To evaluate safety of a two-dose ID93 + GLA-SE vaccine regimen administered 60 days apart on Step 2, Days 0 and 60, with TB treatment administered, at approximately: 1.1.1.1 Months 4 and 6 after start of TB treatment (Group 1) 1.1.1.2 Months 3 and 5 after start of TB treatment (Group 2) 1.1.1.3 Months 2 and 4 after start of TB treatment (Group 3 and Group 5, if this vaccination schedule is adopted for Group 5) 1.1.1.4 Months 1 and 3 after start of TB treatment (Group 4 and Group 5, if this vaccination schedule is adopted for Group 5) 1.1.2 Phase 2a and 2b: To determine if therapeutic vaccination with ID93 + GLA-SE will increase the magnitude of vaccine-specific cellular responses compared to placebo at 2 weeks post second dose of study product. 1.1.3 Phase 2b: To estimate the effect of the vaccine on the proportion of participants with TB-related unfavorable outcomes (treatment failure, TB recurrence, or death due to TB) at Day 540 after study entry, which is approximately 18 months after start of TB treatment (Group 5 combined with either Group 3 or Group 4, depending on which vaccination schedule is selected for Group 5).,
|
Uganda |
2024-06-05 17:42:17 |
2027-06-05 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
KIYINGI MARTIN
ID:
|
A critical review of [Nature of existence]; to establish "Existential Scope of education", the "Problem of education", "Forms of inquiry” and “Perspectives of knowledge”, in Uganda. A case of selected education policy institutions and Universities in Uganda.
REFNo: SS2573ES
4. To explore possibility of Physical (Truth, Empirical Knowledge and Reality), to alleviate the prevailing and emerging, “Existential” and “Physical” problems; probably the prevailing “Scope of education” is focused at mitigation and adaptation rational consequential [Physical problems (Outcomes)] of own continuous existential Causation and Processing. ,3. To explore how the [Nature of existence] influence Existential (Truth, Knowledge & Reality) and establish if possibility of (Truth, Knowledge and Reality) is limited to only the physical possibility of existence.,2. To explore the “Problem of education” and establish how the [Existential forms of inquiry] based on the [Nature of existence] influence the [Perspectives (Viewpoint) of knowledge]. ,1. To explore the fundamental [Nature of existence], a fundamentalism of [Existential Identity] of all species, the “Scope of education” and basis for respective [Existential forms of inquiry (Sensory response to stimulus)].,
|
Uganda |
2024-06-05 17:39:12 |
2027-06-05 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Cornelius Sendagire
ID: UNCST-2021-R004351
|
Potentially modifiable factors to improve outcomes of mechanically ventilated patients in ICUs in Resource-limited settings (MOTIVATE-ICU)
REFNo: HS4040ES
To assess outcomes associated with tracheostomy timing in IMV patients in LMIC ICUs.,To determine non-modifiable patient-level factors associated with ICU mortality, ICU length of stay and duration of mechanical ventilation among LMIC ICU patients. ,To identify potentially modifiable factors associated with ICU mortality, ICU length of stay and duration of mechanical ventilation among LMIC ICU patients. ,
|
Uganda |
2024-06-05 17:37:52 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Jack Turihohabwe
ID:
|
A deep learning model for early prediction and diagnosis of Late Blight Disease in Irish potatoes: A case of Kigezi Region RefNo:MUST-2023-1308
REFNo: SIR323ES
The major objective of the research study is improving early prediction and accurate diagnosis of late blight disease among Irish potato farmers in Kigezi.
|
Uganda |
2024-06-05 17:36:19 |
2027-06-05 |
Engineering and Technology |
Non-Clinical Trial |
Degree Award |
|
Emmanuel Menya
ID:
|
Torrefaction of Banana Value Chain-Based Wastes Available in Uganda for Fuel (TorrCoal Project)
REFNo: SIR172ES
Main Objective
To investigate the torrefaction potential of banana value chain-based wastes available in Uganda for fuel.
Specific Objectives
• To characterize the underutilized banana value chain-based wastes
• To optimize the torrefaction conditions for production of bio-coal from selected banana value chain-based wastes
• To assess the quality and performance of briquettes generated from the torrefied banana waste
|
Uganda |
2024-06-05 17:35:18 |
2027-06-05 |
Engineering and Technology |
Non-Clinical Trial |
Degree Award |
|
Adeline Boatin
ID: UNCST-2019-R001255
|
Education of pregnant women with a prenatal indication for cesarean section through periodic short message service (SMS) and interactive voice response system (IVR) in Uganda
REFNo: HS4081ES
1. To pilot the use of SMS and IVR among high-risk pregnant women scheduled for elective caesarean section and receiving antenatal care at the Mbarara Regional Referral Hospital in Uganda.
2.a)To determine the acceptability of SMS and IVR among high-risk pregnant women among high risk pregnant women scheduled for elective caesarean section.
2.b)To determine the feasibility of using SMS and IVR for education among high risk pregnant women scheduled for elective caesarean section.
|
Ghana |
2024-06-05 17:34:20 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Benson Musinguzi
ID:
|
MOLECULAR EPIDEMIOLOGY OF OROPHARYNGEAL CANDIDA SPECIES ISOLATED FROM PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS ATTENDING TASO CLINICS IN UGANDA
REFNo: HS3823ES
Sub study 4. Molecular relatedness of oropharyngeal Candida species isolated from people living with HIV attending TASO clinics in Uganda.,Sub study 3. Virulence attributes in oropharyngeal Candida species isolated from people living with HIV attending TASO clinics in Uganda,,Sub study 2. Prevalence of OPC and antifungal susceptibility profile of oropharyngeal Candida species isolated from people living with HIV attending TASO clinics in Uganda, ,Sub study 1. Prevalence of oropharyngeal candidiasis and distribution of Candida species among people living with HIV in Africa: a systematic review and meta-analysis,MOLECULAR EPIDEMIOLOGY OF OROPHARYNGEAL CANDIDA SPECIES ISOLATED FROM PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS ATTENDING TASO CLINICS IN UGANDA,
|
Uganda |
2024-06-05 17:31:38 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Ronald Olum
ID: UNCST-2021-R013821
|
Feasibility, Acceptability and Preliminary Effect of Community-Led HIV Self-Testing Intervention Among Adolescent Girls and Young Women in Rural Northern Uganda.
REFNo: HS4043ES
To assess the preliminary impact of the peer-delivered CHW-facilitated HIVST model on HIV self-testing rates and linkage to care among AGYW. ,To evaluate the feasibility and acceptability of the peer-delivered community health worker-facilitated HIV self-testing intervention in Northern Uganda.,To develop a peer-delivered community health worker-facilitated HIV self-testing model tailored to the needs of adolescent girls and young women n Northern Uganda.,The overall aim of this study is to establish a sustainable, community-based HIV self-testing model that effectively increases HIV rates and linkage to care among adolescent girls and young women n Northern Uganda.,
|
Uganda |
2024-06-05 17:30:10 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Peter Kangwagye
ID: UNCST-2023-R005510
|
EARLY DETECTION OF ATRIAL FIBRILLATION AMONG RHEUMATIC HEART DISEASE PATIENTS WITH MODERATE OR SEVERE LESIONS IN SINUS RHYTHM
REFNo: HS4027ES
2. To document the factors associated with AF among patients attending the RHD clinic of MRRH,1. To determine the prevalence of AF among patients attending the RHD clinic of MRRH,To determine the prevalence of atrial fibrillation (AF) among patients with RHD in Mbarara Regional Referral Hospital (MRRH),
|
Uganda |
2024-06-05 17:26:45 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Lydia Kabiri Watsemwa
ID: UNCST-2020-R014567
|
Exploring the rationale for an integrated preventive approach to child health in Uganda: Perspectives from families, health care givers and non-health stakeholders
REFNo: HS3931ES
To understand challenges, opportunities, and possible improvements in the current system for preventive child health care in Uganda;
To explore opportunities, barriers, and facilitating factors for creating and implementing a future permanent system for preventive child health, suitable for multisectoral collaboration;
To understand how caregivers currently identifies early signs of illness and developmental delay among young children;
To understand how caregivers and other stakeholders view the possibility for improved knowledge of early signs of illness as well as early screening for and identification of developmental delay and disability among young children.
|
Uganda |
2024-06-05 17:23:17 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Zenah Nantumbwe
ID:
|
A Mental Health Literacy intervention for adolescents in secondary school in Uganda: Implementation and evaluation of “The Wellness Project”
REFNo: HS4071ES
To examine if The Wellness Project intervention has a positive impact on MH care referral system and explore acceptability of MHL intervention program among adolescents and key health contacts. ,To investigate if mental health literacy psychoeducational program will increase mental health - illness knowledge, reduce stigma attitudes towards mental illness and increase help seeking knowledge and intentions among adolescents. ,To access the mental health-illness knowledge, stigma attitudes towards mental illness, help seeking behaviour and school MH care of adolescents in secondary school.,
|
Uganda |
2024-06-05 17:21:06 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Dennis Kalibbala
ID:
|
Effectiveness and implementation of HIV self-testing distribution through the Young People and Adolescents Peer Support (YAPS) model in Uganda
REFNo: HS4089ES
3. To explore the effectiveness of HIVST through the YAPS model on linkage to care and treatment outcomes among those who test positive,2. To assess the acceptability and feasibility of HIVST distribution through the YAPS model among young people and adolescents in Uganda.,1. To identify the factors that influence the implementation of HIVST through the YAPS model.,To determine implementation and effectiveness of HIV self-testing through the Young People and Adolescents Peer Support (YAPS) model in Uganda,
|
Uganda |
2024-06-05 17:19:50 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Harriet Aber
ID:
|
Assessing the effect of Climatic Variables on the Prevalence of Malaria and Meningitis, and Health Worker Perceptions of Climate Change Health Impacts in Northern Uganda.
REFNo: HS3706ES
1. To describe the trends in climate variability, malaria and meningitis prevalence between January 1, 2000, to December 31, 2020, within the districts of Amuru, Gulu, Nwoya, Omoro, and Gulu City.
2. To assess the effect of climatic variables (precipitation, temperature, humidity) on the prevalence of malaria and meningitis between January 1, 2000, to December 31, 2020, within the districts of Amuru, Gulu, Nwoya, Omoro, and Gulu City.
3. To explore the perceptions of primary healthcare professionals (HCP) and district managers in the districts of Amuru, Gulu, Nwoya, Omoro, and Gulu City regarding the impact of climate variability on malaria and meningitis prevalence, as well as explore potential adaptation initiatives to mitigate its effects on the health of populations.
|
Uganda |
2024-06-05 17:17:56 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Kevin Komakech
ID: UNCST-2023-R005979
|
Evaluation of Point-of-Care Triage Tests to Aid in Tuberculosis Diagnosis
REFNo: HS4153ES
4. To evaluate the effect of sputum microbiome on the diagnostic performance of selected point of care TB triage test among presumptive TB patients,3. To determine the cost effectiveness of using a point of care TB triage test among presumptive TB patients,2. To determine the diagnostic performance (sensitivity, specificity, positive and negative predictive value) of different point of care TB triage test among presumptive TB patients in a single study ,1. To evaluate the performance of point of care triage tests for pulmonary tuberculosis through a systematic review and meta-analysis ,
|
Uganda |
2024-06-05 17:16:53 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Stavia Turyahabwe Stavia
ID: UNCST-2022-R011373
|
Contribution of Mobile TB Clinic Fitted with Digital X-ray, CAD and Xpert MTB/RIF/Ultra on same day TB diagnosis and treatment initiation in Uganda.
REFNo: HS3797ES
General Objective
The goal of the study is to assess the usefulness of portable X-ray, CAD and GeneXpert fitted on Mobile TB clinic in enhancing TB detection and initiation of treatment among high risk patients in Uganda.
Specific Objectives
1. To determine the uptake of “enhanced” mobile TB clinic services using targeted active case finding outreaches/activities among the high-risk communities in Uganda.
2. To determine the operational feasibility and cost effectiveness of mobile TB clinics to conducting same day TB screening, diagnosis and treatment initiation.
3. To evaluate the diagnostic performance of CAD4TB using Xpert MTB/Rif ultra as the reference standard.
|
Uganda |
2024-06-05 17:15:45 |
2027-06-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Samuel Onep George
ID:
|
DEVELOPMENT OF A DOWNDRAFT GASIFIER USING BIOMASS GASIFICATION PROCESS FOR POWERING A COMMERCIAL FEED MILL
REFNo: SIR334ES
iv. To evaluate the performance of the downdraft biomass gasifier prototypes in terms of quality of the syngas and thermal efficiency under practical operating conditions. ,iii. To optimize process parameters of equivalent ratio, moisture content and reaction temperature to produce syngas with tar content less that 0.1 g/m3 and carbon dioxide percentage less than 5%,ii. To design and fabricate a downdraft gasifier prototype with a thermal power output of 5KW, Specific Gasification Rate of 2000 m3/m2hr, and able to achieve thermal efficiency of 60%.,i. To characterize groundnut shells and pine wood chippings in order to determine their appropriateness for gasification basing on their calorific value, ash content, fixed carbon, physical features and presence of contaminants.,The aim of this research is to develop a downdraft biomass gasifier for powering a mill for commercial production of animal feeds,
|
Uganda |
2024-06-05 17:13:40 |
2027-06-05 |
Engineering and Technology |
Non-Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|